Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 726-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 386-394

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

By Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

No evidence for accumulation of insulin glargine (LANTUS®): a multiple injection study in patients with Type 1 diabetes

By  

DIABETIC MEDICINE, Vol. 19, Iss. 6, 2002-06 ,pp. : 490-495

John Wiley & Sons Inc

Access to resources Recommend Favorite